Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0203


New standard targeted therapy for pancreatic neuroendocrine tumors.

Dr. John Spiliotis, MD.

Affiliation: Dr. John Spiliotis, Head of Department of Surgery, "METAXA" Cancer Memorial Hospital, Botosi 51, TK 18535, Piraeus, Greece.


Over the past two decades no systemic therapy has been established as standard in the treatment of patients with neuroendocrine tumors in the pancreas. Targeted therapy alone or in combination with chemotherapy has revolutionized systemic treatment of cancer over the last 13 years after a first approval of a monoclonal antibody. Since then, the field of small molecules receptors tyrosine kinase (RTKs) inhibitors has rapidly being expanded included many such signal transduction drugs for various cancer types. Two of these drugs, everolimus and sunitinib have demonstrated substantial antitumor activity in experimental and clinical studies. In this review, the advances in diagnostics, tumor staging, and treatment of patients with pancreatic neuroendocrine tumors with particular emphasis on targeted drugs and their efficacy and safety are discussed considering the results of recent phase 3, randomized trials.

(Citation: Gastric & Breast Cancer 2012; 11(1) 44-49)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 January 2012